ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / OSTX / earnings
APLM (55) SPRO (40) INCR (46) XBIT (32) ⌘ Pro Terminal →

OS Therapies Incorporated (OSTX) Next Earnings Date & Expected ±12.5% Move

$1.16 +0.87% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.16

OS Therapies Incorporated (OSTX) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $59.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OSTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OSTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, OS Therapies Incorporated (NYSE: OSTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.16 (+0.87% 1D, market cap $59.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OSTX ranks #804 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OSTX compare to APLM and SPRO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OSTX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APLM (Apollomics Inc. (Class A)) holds a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $60.4M) and SPRO (Spero Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E 7.5x, ROIC 26.6%, cap $60.6M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OSTX?
▼

Per OSTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001795091), OS Therapies Incorporated generated $80.4M in revenue (+321.3% YoY), -$28.8M in net income, and -$14.2M in free cash flow against $6.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.16 (-0.03%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (7)Whales (3)SEC (10)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.9% Base Target
$2 Bull$1 Base$1 Bear
📬 FREE OSTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OSTX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY OSTX SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
38
Grade E$1.45-13.1% Next Q
Q2 (-2Q)
35
Grade E$1.26-2.4% Next Q
Q3 (-1Q)
33
Grade E$1.23-5.7% Next Q
Current
30
Grade E$1.16-9.6% Hist 90D α
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OSTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OSTX currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.56) and Max Pain ($1.22) forces dealer call-delta covering toward $2.36.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OSTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OSTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.14 Expected Swing
$1.02 (-12.5%)Spot $1.16$1.30 (+12.5%)
MODEL EARNINGS SETUP GAUGE

OSTX Quantitative Pre-Earnings Setup: 30/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (30/100)Model Risk Weight (70/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$80.4M-$28.8M-$14.2M52%
FY 20242024-12-31$19.1M-$8.9M-$7.3M52%
FY 20232023-12-31$12.2M-$7.8M-$3.0M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OSTX)

  • ✓Walkthrough of OSTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
OSTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -32.95%▼ SUPPORT BREAKDOWN
2026-11-04O $1.24H $1.24L $1.15C $1.16VOL 933.0K
RES: $1.83SUP: $1.17SMA50: $1.56SMA200: $1.56
$2.33$2.01$1.69$1.37$1.05RES $1.83SUP $1.17$1.162026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OSTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OSTX Butterfly Map → + Track OSTX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +321.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on OSTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OSTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OSTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OSTX)

Health Care Rank #804 of 1015 ⚔️ APLM vs OSTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OSTX vs. APLM, SPRO, INCR, XBIT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, OS Therapies Incorporated (OSTX) ranks #804 by composite RQD confidence (30/100, grade E) and #716 by equity capitalization ($59.8M). Within this direct 5-issuer industry benchmark cohort, SPRO leads on earnings valuation at 7.5x trailing P/E, while SPRO leads on capital efficiency and profitability with 26.6% ROIC and — gross margin. APLM currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with OSTX at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
OSTX ACTIVE
OS Therapies Incorporated
E 30/100 — — -35.0% +0.87% $59.8M Benchmark Subject
APLM
Apollomics Inc. (Class A)
D+ 55/100 — — — 0.00% $60.4M /aplm-vs-ostx →
SPRO
Spero Therapeutics Inc.
D- 40/100 7.5x — 26.6% 0.00% $60.6M /spro-vs-ostx →
INCR
Intercure Ltd.
D 46/100 — — — -0.74% $60.8M /incr-vs-ostx →
XBIT
XBiotech Inc.
E 32/100 — — -35.0% +3.65% $58.5M /xbit-vs-ostx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001795091 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), OS Therapies Incorporated (OSTX) reported GAAP revenue of $80.4M (+321.3% vs. FY2024 revenue of $19.1M , and +561.0% cumulative change since FY2023) , GAAP net income of -$28.8M, operating cash flow of -$14.2M, and free cash flow of -$14.2M (-95.5% YoY). On the balance sheet, OSTX closed FY2025 with $6.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $80.4M -$28.8M -$14.2M -$14.2M $6.8M —
FY2024 (FY) 2024-12-31 $19.1M -$8.9M -$7.3M -$7.3M $5.5M —
FY2023 (FY) 2023-12-31 $12.2M -$7.8M -$3.0M -$3.0M — —

3. OSTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OSTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, OS Therapies Incorporated (NYSE: OSTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.16 (+0.87% 1D, market cap $59.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OSTX ranks #804 in composite RQD confidence.

How does OSTX compare to APLM and SPRO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OSTX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APLM (Apollomics Inc. (Class A)) holds a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $60.4M) and SPRO (Spero Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E 7.5x, ROIC 26.6%, cap $60.6M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OSTX?

Per OSTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001795091), OS Therapies Incorporated generated $80.4M in revenue (+321.3% YoY), -$28.8M in net income, and -$14.2M in free cash flow against $6.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OSTX trading relative to its 50-day, 200-day, and 52-week technical levels?

OSTX last traded at $1.16 (+0.87% on volume of 439,311 shares), positioning the stock -25.64% below its 50-day simple moving average ($1.56) and -25.64% below its 200-day simple moving average ($1.56). Across its 52-week range of $1.15 to $2.25, OSTX sits at the 0.9% percentile with a 14-day RSI of 28.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.02 to $1.30).

Direct Sub-Reports: OSTX RQD Cockpit OSTX 12M Forecast OSTX Earnings & Move OSTX Dividends & DRIP OSTX Insiders & 13F OSTX Whale Options OSTX Profit Sankey OSTX News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

OSTX — OS Therapies Incorporated: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

OS Therapies Incorporated (OSTX) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.16 (+0.87% 1D, market capitalization $59.8M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -21.07%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

— The sector is Health Care and the industry is Biotechnology: Pharmaceutical Preparations. The profile describes OS Therapies Incorporated as a NYSE-listed issuer. Products, customers, and revenue model are not described in the source data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), OS Therapies Incorporated (OSTX) reported $80.4M in annual revenue (up from $19.1M in FY2024, +321.3% YoY) and -$28.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($12.2M revenue, -$7.8M net income) through FY2025, OSTX scaled operating cash flow to -$14.2M and free cash flow to -$14.2M, backed by $6.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -21.07% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.15 – $2.25 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream dependencies, no listed sector correlations, and no proprietary signals. — for supplier, customer, or bottleneck mapping.

  • Key Question #1: Can OSTX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $80.4M and free cash flow of -$14.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is OSTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

OSTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for OS Therapies Incorporated (OSTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OSTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OSTX Bull vs. Bear Conversation Board — What's Your Call at $1.16?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OSTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on OSTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $1.60 (+29.0%)
📌 Pinned Debate

Institutional accumulation and options positioning score 11/20 in the RQD rating, and a reported 72.7% three-year survival figure appea

The street is overcomplicating OS Therapies Incorporated (OSTX). Institutional accumulation and options positioning score 11/20 in the RQD rating, and a reported 72.7% three-year survival figure appears in the news wire.. With an RQD score of 30/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.34.

VolSurface_Trader 🐂 BULL

Both sides have a point here — OSTX's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $1.00 (-19.4%)
Spot @ $1.24

ROIC of -35%, FCF yield of -21.07%, and reported revenue of $0.0M with FY 2025 net loss of -$28.8M point to a weak cash engine.

I respect the product at OS Therapies Incorporated, but the stock at $1.24 is a different story. ROIC of -35%, FCF yield of -21.07%, and reported revenue of $0.0M with FY 2025 net loss of -$28.8M point to a weak cash engine.. FCF yield is -21.07% and RQD sits at 30/100 (E) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE